Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding ev...
Publications
View All2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary
Symptomatic AF prior to initiation of antiarrhythmic therapy with a Class I or III antiarrhythmic medication Paroxysmal: Surgical ablation is reasonable.IIa
Institution Info
- Type
- healthcare
- Country
- GB
- Publications
- 2
- Citations
- 1,481
External Links
Identifiers
- ROR
- https://ror.org/02218z997